SCCA is changing the way cancer is treated and cured.
The promise of immunotherapy is boosting survival rates for patients with lung cancer, melanoma, leukemia and many other cancers. Our patients have access to a greater number of immunotherapy treatments in clinical trials and FDA-approved therapies—many available only at Seattle Cancer Care Alliance.
Our researchers are discovering new ways to tap into the immune system's inherent disease-fighting power and give it the upper hand against cancer.
Axi-cel (YESCARTA™) — New FDA-approved CAR T-cell therapy
SCCA is one of the first cancer centers in the nation, and the only center in the Northwest, to offer axicabtagene ciloleucel (axi-cel), also known by the brand name YESCARTA™. This new immunotherapy uses engineered cell therapy to harnesses the power of a patient’s own immune system to treat adults with aggressive non-Hodgkin lymphoma (NHL).
Learn more about axi-cel treatment at SCCA.